|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Recombx® CV2 Autoantibody Test (Autoimmune Rapidly Progressive Dementia)
Test Code1717
CPT Codes
83520
Preferred Specimen
2 mL serum
Minimum Volume
0.5 mL
Other Acceptable Specimens
CSF collected in a sterile, leak-proof container
Instructions
Note: Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Serum must be separated from cells within 48 hours of collection.
Serum must be separated from cells within 48 hours of collection.
Transport Container
Plastic screw-cap vial
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Methodology
Automated Nanoliter Scale Immunoassay
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon-Fri; Report Available: 3-5 days
Reference Range
Serum
CSF
Technical Results | <1:100 |
CSF
Technical Results | <1:1 |
Clinical Significance
Anti-CV2 autoantibody is found in patients with autoimmune Rapidly Progressive Dementia. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.